Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR ‐mutated non‐small‐cell lung cancer: A case report

A therapeutic option for advanced non‐small‐cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) resistance is a clinical challenge. The clinical outcomes of pembrolizumab in those patients is inconclusive. Cytokine release syndrome (CRS) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Meng, Cheng, Yuan, Hu, Yan, Nie, Ligong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058301/
https://www.ncbi.nlm.nih.gov/pubmed/35384319
http://dx.doi.org/10.1111/1759-7714.14390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058301/
https://www.ncbi.nlm.nih.gov/pubmed/35384319
http://dx.doi.org/10.1111/1759-7714.14390

Ejemplares similares